Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Future Oncology

• Publication date

  2014-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.14.164PMID 25471031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice

  2013cited by this paper
• Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells.

  2013cited by this paper
• Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression.

  2013cited by this paper
• Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge.

  2013cited by this paper
• Immunotherapy: Cancer immunotherapy for the elderly

  2013cited by this paper
• Targeting EGFR‐positive cancer cells with cetuximab–ZZ‐PE38: Results of in vitro and in vivo studies

  2013cited by this paper
• The toxin component of targeted anti‐tumor toxins determines their efficacy increase by saponins

  2012cited by this paper
• Saponins modulate the intracellular trafficking of protein toxins.

  2012cited by this paper
• Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.

  2012cited by this paper
• Prediction in rectal cancer.

  2012cited by this paper
• Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin.

  2012cited by this paper
• Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement.

  2012cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis.

  2010cited by this paper
• Evaluating the Age Distribution of Patients With Colorectal Cancer: Are the United States Preventative Services Task Force Guidelines for Colorectal Cancer Screening Appropriate?

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• A convenient method for saponin isolation in tumour therapy.

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Sex hormones and colorectal cancer: what have we learned so far?

  2010cited by this paper
• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  2010cited by this paper
• Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors.

  2009cited by this paper
• Worldwide Variations in Colorectal Cancer

  2009cited by this paper
• Recommendations on the Use of 18F-FDG PET in Oncology

  2008cited by this paper
• EGFR and colon cancer: a clinical view

  2008cited by this paper
• ErbB1–ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer

  2007cited by this paper
• A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice.

  2007cited by this paper
• Immunotoxins for targeted cancer therapy

  2006cited by this paper
• In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

  2006cited by this paper
• Comparing antibody and small-molecule therapies for cancer

  2006cited by this paper
• Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma

  2005cited by this paper
• Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.

  2005cited by this paper
• A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

  2005cited by this paper
• Immunotoxins and other conjugates: pre-clinical studies.

  2004cited by this paper
• Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.

  2004cited by this paper
• Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

  2004cited by this paper
• Phase I study of anticolon cancer humanized antibody A33.

  2003cited by this paper
• Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved

  2003cited by this paper
• A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins

  2003cited by this paper
• Ribosome‐inactivating proteins depurinate poly(ADP‐ribosyl)ated poly(ADP‐ribose) polymerase and have transforming activity for 3T3 fibroblasts

  2003cited by this paper
• Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.

  2002cited by this paper
• Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

  2002cited by this paper
• Immunotoxins for targeted cancer therapy.

  1998cited by this paper
• Accumulation of 2-deoxy-2[18F]fluoro-D-glucose in human cancers heterotransplanted in nude mice: comparison between histology and glycolytic status.

  1994cited by this paper
• Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

  1993cited by this paper
• Immunological properties of ribosome-inactivating proteins and a saporin immunotoxin.

  1992cited by this paper
• Dianthins, ribosome-damaging proteins with anti-viral properties from Dianthus caryophyllus L. (carnation).

  1981cited by this paper

• Recombinant Expression of a Ready‐to‐Use EGF Variant Equipped With a Single Conjugation Site for Click‐Chemistry

  2025cites this paper
• A cleavable peptide adapter augments the activity of targeted toxins in combination with the glycosidic endosomal escape enhancer SO1861

  2024cites this paper
• Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861

  2023cites this paper
• Saponin Fraction CIL1 from Lysimachia ciliata L. Enhances the Effect of a Targeted Toxin on Cancer Cells

  2023cites this paper
• Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer.

  2023cites this paper
• Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861

  2022cites this paper
• Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861

  2021cites this paper
• Generation of a soluble and stable apoptin-EGF fusion protein, a targeted viral protein applicable for tumor therapy.

  2020cites this paper
• Building the case for the calcitonin receptor as a viable target for the treatment of glioblastoma

  2020cites this paper
• Structure-Activity Relationship of Transfection-Modulating Saponins – A Pursuit for the Optimal Gene Trafficker

  2019cites this paper
• Dianthin and Its Potential in Targeted Tumor Therapies

  2019influential citation
• Effect of pH on photosynthesized silver nanoparticles using Dianthus caryophyllus L. (Carnation) flower

  2018cites this paper
• Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma

  2018cites this paper
• differentially potent in vitro in high grade 2 glioma cell lines derived from glioblastoma 3 4

  2017cites this paper
• Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies

  2017cites this paper
• Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

  2017influential citation
• Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861

  2017cites this paper
• Chemical contents and medical importance of Dianthus caryophyllus- A review

  2017cites this paper
• New perspectives for natural triterpene glycosides as potential adjuvants.

  2017cites this paper
• Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions)

  2017cites this paper
• Anticancer effects of Arabian medicinal plants (part 1) - A review

  2017cites this paper
• Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers

  2016cites this paper
• Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

  2016cites this paper
• Structures and Ribosomal Interaction of Ribosome-Inactivating Proteins

  2016cites this paper
• Enhanced anti-tumor activity of trichosanthin after combination with a human-derived cell-penetrating peptide, and a possible mechanism of activity.

  2016cites this paper
• Phenolics-saponins rich fraction of defatted kenaf seed meal exhibits cytotoxicity towards cancer cell lines

  2016cites this paper
• Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861.

  2015cites this paper
• Development of a platform technology for enhanced endo/lysosomal escape of targeted toxins by structurally specific oleanane saponins

  2014cites this paper
• The Anterior Spreader Flap: A Minimally Invasive Alternative to the Auto Spreader Flap in the Treatment of Patients with Nasal Valve Dysfunction

  2014cites this paper